OFAX Tablet

Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae or Streptococcus pneumoniae.

Community-acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae.

Uncomplicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabillis.

Acute, uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae.

Nongonococcal urethritis and cervicitis due to Chlamydia trachomatis and Neisseria gonorrhoeae.

Acute pelvic inflammatory disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae.

NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered.

Uncomplicated cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabillis, or Pseudomonas aeruginosa.

Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabillis, Citrobacter diversus, or Pseudomonas aeruginosa.

Prostatitis due to Escherichia coli.

Dosage and Administration

The usual dose is 200-400mg orally every 12 hours.

In persons with a history of hypersensitivity associated with the use of ofloxacin or any member of the quinolone group of antimicrobial agents.

Ofloxacin may cause some unwanted or undesirable effects. Generally, ofloxacin is well tolerated most patients will not experience unwanted effects. The frequency and severity of these effects is dependant on many factors including dose, duration of therapy and individual susceptibility. Possible unwanted effects include diarrhea, nausea, vomiting, headache, dizziness, troubles sleeping, external genital itchiness in women.

Antacids that contain aluminum or magnesium, probenecid, iron or mineral supplements, zinc-containing products, warfarin, hypoglycemic drugs, cyclosporine, sucralfate, theophylline.

These agents should not be taken within the 2 hour period before or within the 2 hour period after ofloxacin administration.

The safety and efficacy of ofloxacin in pregnant women and lactating women have not been established.

The safety and efficacy of ofloxacin in pediatric patients and adolescents (under the age of 18 years), pregnant women and lactating women have not been established.

Ofloxacin, acts on DNA gyrase, an enzyme which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription.